Key Points
- Director Isaac Barchas sold 383,200 shares at an average price of $21.74 on Dec. 22 for a total of $8.33M and now directly owns 2,031,181 shares — a 15.87% reduction in his position.
- Immunome shares opened around $21.73 with a market cap of about $1.99B and a 12‑month range of $5.15–$25.30; the company is still unprofitable after reporting a quarterly EPS of ($0.65), missing estimates and showing deeply negative ROE and net margin.
- Analysts are mostly bullish (10 Buys, 1 Sell) with a consensus target of $30.09 and several firms setting price targets up to $40, while institutional investors own roughly 44.6% of the stock.
Immunome, Inc. (NASDAQ:IMNM - Get Free Report) Director Isaac Barchas sold 383,200 shares of the company's stock in a transaction on Monday, December 22nd. The stock was sold at an average price of $21.74, for a total value of $8,330,768.00. Following the sale, the director directly owned 2,031,181 shares in the company, valued at $44,157,874.94. This represents a 15.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Immunome Trading Down 1.4%
Shares of NASDAQ IMNM opened at $21.73 on Wednesday. The stock has a market cap of $1.99 billion, a P/E ratio of -7.37 and a beta of 2.17. The business's fifty day simple moving average is $17.99 and its 200-day simple moving average is $12.91. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $25.30.
Immunome (NASDAQ:IMNM - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, equities analysts forecast that Immunome, Inc. will post -2.21 EPS for the current fiscal year.
Institutional Trading of Immunome
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMNM. Assetmark Inc. acquired a new position in shares of Immunome in the 3rd quarter valued at $39,000. BIT Capital GmbH acquired a new stake in Immunome during the 3rd quarter worth $69,000. BNP Paribas Financial Markets boosted its stake in Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock valued at $60,000 after acquiring an additional 2,909 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Immunome during the third quarter worth about $76,000. Finally, Tower Research Capital LLC TRC increased its position in shares of Immunome by 121.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after purchasing an additional 3,802 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company's stock.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. Craig Hallum began coverage on shares of Immunome in a research note on Friday, September 5th. They set a "buy" rating and a $26.00 target price on the stock. Lake Street Capital increased their price objective on shares of Immunome from $22.00 to $32.00 and gave the company a "buy" rating in a research report on Tuesday, December 16th. Truist Financial assumed coverage on shares of Immunome in a report on Monday, December 1st. They issued a "buy" rating and a $36.00 price objective on the stock. Leerink Partners set a $40.00 price objective on shares of Immunome in a research report on Monday, December 15th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Immunome in a report on Wednesday, October 8th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $30.09.
Read Our Latest Research Report on Immunome
Immunome Company Profile
(
Get Free Report)
Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome's approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.
The company's lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
